Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
J Med Virol. 2020 Apr; 92(4): 418–423.
Published online 2020 Feb 7. doi: 10.1002/jmv.25681
PMCID: PMC7167049
PMID: 31967327

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Yu Chen,corresponding author 1 Qianyun Liu, 1 and Deyin Guocorresponding author 2
Author information Article notes Copyright and License information PMC Disclaimer

Abstract

The recent emergence of a novel coronavirus (2019‐nCoV), which is causing an outbreak of unusual viral pneumonia in patients in Wuhan, a central city in China, is another warning of the risk of CoVs posed to public health. In this minireview, we provide a brief introduction of the general features of CoVs and describe diseases caused by different CoVs in humans and animals. This review will help understand the biology and potential risk of CoVs that exist in richness in wildlife such as bats.

Keywords: coronavirus, epidemiology, pathogenesis, respiratory tract, virus classification, zoonoses

Highlights

  • The general features of coronaviruses are introduced.
  • The risk of emerging coronaviruses including the 2019‐nCoV is described.
  • The genome structure and replication mechanism of coronaviruses are provided.
  • The diseases caused by the major coronaviruses are listed.

1. INTRODUCTION

Coronaviruses (CoVs) are important pathogens for human and vertebrates. They can infect respiratory, gastrointestinal, hepatic, and central nervous system of human, livestock, birds, bat, mouse, and many other wild animals. 1 , 2 , 3 The outbreaks of the severe acute respiratory syndrome (SARS) in 2002/2003 and the Middle East respiratory syndrome (MERS) in 2012 have demonstrated the possibility of animal‐to‐human and human‐to‐human transmission of newly emerging CoVs. 4 , 5 An outbreak of mystery pneumonia in Wuhan since December 2019 has been drawing tremendous attention around the world. Chinese government and researchers have been taking swift measures to control the outbreak and conduct the etiological studies. The causative agent of the mystery pneumonia has been identified as a novel coronavirus (nCoV) by deep sequencing and etiological investigations by at least five independent laboratories of China (http://virological.org/ and https://www.gisaid.org/). On 12 January 2020, the World Health Organization temporarily named the new virus as 2019 novel coronavirus (2019‐nCoV). The sporadic emergence and outbreaks of new types of CoVs remind us that CoVs are a severe global health threat. It is highly likely that new CoV outbreaks are unavoidable in the future due to changes of the climate and ecology, and the increased interactions of human with animals. Thus, there is an urgent need to develop effective therapies and vaccines against CoVs.

2. CORONAVIRAL GENOME STRUCTURE AND REPLICATION

CoVs belong to the subfamily Coronavirinae in the family of Coronaviridae of the order Nidovirales, and this subfamily includes four genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus (Figure 1A). The genome of CoVs is a single‐stranded positive‐sense RNA (+ssRNA) (~30 kb) with 5′‐cap structure and 3′‐poly‐A tail. The genomic RNA is used as template to directly translate polyprotein 1a/1ab (pp1a/pp1ab), which encodes nonstructural proteins (nsps) to form the replication‐transcription complex (RTC) in a double‐membrane vesicles (DMVs). 6 Subsequently, a nested set of subgenomic RNAs (sgRNAs) are synthesized by RTC in a manner of discontinuous transcription. 7 These subgenomic messenger RNAs (mRNAs) possess common 5′‐leader and 3′‐terminal sequences. Transcription termination and subsequent acquisition of a leader RNA occurs at transcription regulatory sequences, located between open reading frames (ORFs). These minus‐strand sgRNAs serve as the templates for the production of subgenomic mRNAs. 8 , 9

An external file that holds a picture, illustration, etc. Object name is JMV-92-418-g001.jpg

The genomic structure and phylogenetic tree of coronaviruses. A, The phylogenetic tree of representative CoVs, with the new coronavirus 2019‐nCoV highlighted in red. B, The genome structure of four genera of coronaviruses. Pp1a and pp1b represent the two long polypeptides that are processed into 16 nonstructural proteins. S, E, M, and N indicate the four structural proteins spike, envelope, membrane, and nucleocapsid. 2019‐nCoV, 2019 novel coronavirus; CoVs, coronavirus; HE, hemagglutinin‐esterase. Viral names: HKU, coronaviruses identified by Hong Kong University; HCoV, human coronavirus; IBV, infectious bronchitis virus; MHV, murine hepatitis virus; TGEV, transmissible gastroenteritis virus

The genome and subgenomes of a typical CoV contain at least six ORFs. The first ORFs (ORF1a/b), about two‐thirds of the whole genome length, encode 16 nsps (nsp1‐16), except Gammacoronavirus that lacks nsp1. There is a −1 frameshift between ORF1a and ORF1b, leading to production of two polypeptides: pp1a and pp1ab. These polypeptides are processed by virally encoded chymotrypsin‐like protease (3CLpro) or main protease (Mpro) and one or two papain‐like protease into 16 nsps. 10 , 11 Other ORFs on the one‐third of the genome near the 3′‐terminus encodes at least four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. Besides these four main structural proteins, different CoVs encode special structural and accessory proteins, such as HE protein, 3a/b protein, and 4a/b protein (Figure 1B, lower panel). All the structural and accessory proteins are translated from the sgRNAs of CoVs. 7

The genome sequence alignment of CoVs shows 58% identity on the nsp‐coding region and 43% identity on the structural protein‐coding region among different CoVs, with 54% at the whole genome level (Figure 1B, upper panel), suggesting the nsps are more conserved and the structural proteins are more diverse in need of adaptation to new hosts. Since the mutation rates in the replication of RNA viruses are much higher than that of DNA viruses, the genomes of RNA viruses are usually less than 10 kb in length. However, the CoV genome is much larger, with roughly 30 kb in length, the largest known RNA viruses. The maintenance of such a large genome of CoVs may be related to the special features of the CoV RTC, which contains several RNA processing enzymes such as the 3′‐5′ exoribonuclease of nsp14. The 3′‐5′ exoribonuclease is unique to CoVs among all RNA viruses, probably providing a proofreading function of the RTC. 12 , 13 , 14 Sequence analysis shows that the 2019‐nCoV possesses a typical genome structure of CoV and belongs to the cluster of betacoronaviruses that includes Bat‐SARS‐like (SL)‐ZC45, Bat‐SL ZXC21, SARS‐CoV, and MERS‐CoV. Based on the phylogenetic tree of CoVs, 2019‐nCoV is more closely related to bat‐SL‐CoV ZC45 and bat‐SL‐CoV ZXC21 and more distantly related to SARS‐CoV (Figure 1A).

3. FUNCTIONS OF NONSTRUCTURAL AND STRUCTURAL PROTEINS IN CORONAVIRAL REPLICATION

Most of the nsps of nsp1‐16 have been reported for their specific roles in the replication of CoVs. However, the functions of some of the nsps are unknown or not well understood. The known functions of the 16 nsps are summarized in Table 1.

Table 1

The 16 nonstructural proteins of coronaviruses and their functions

nspsFunctionsReferences
nsp1Cellular mRNA degradation, inhibiting IFN signaling 15 , 16
nsp2Unknown 17 , 18
nsp3PLP, polypeptides cleaving, blocking host innate immune response, promoting cytokine expression 19 , 20
nsp4DMV formation 21 , 22
nsp53CLpro, Mpro, polypeptides cleaving, inhibiting IFN signaling 23 , 24 , 25
nsp6Restricting autophagosome expansion, DMV formation 26 , 27
nsp7Cofactor with nsp8 and nsp12 28 , 29
nsp8Cofactor with nsp7 and nsp12, primase 28 , 29 , 30
nsp9Dimerization and RNA binding 31 , 32
nsp10Scaffold protein for nsp14 and nsp16 33 , 34 , 35 , 36
nsp11Unknown 37
nsp12Primer dependent RdRp 28 , 38 , 39
nsp13RNA helicase, 5′ triphosphatase 40 , 41 , 42
nsp14Exoribonuclease, N7‐MTase 12 , 43 , 44 , 45
nsp15Endoribonuclease, evasion of dsRNA sensors 46 , 47 , 48
nsp162′‐O‐MTase; avoiding MDA5 recognition, negatively regulating innate immunity 34 , 35 , 49

Abbreviations: 3CLpro, chymotrypsin‐like protease; DMV, double‐membrane vesicle; dsRNA, double‐stranded RNA viruses; IFN, interferon; mRNA, messenger RNA; Mpro, main protease.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

Four structural proteins are essential for virion assembly and infection of CoVs. Homotrimers of S proteins make up the spikes on the viral surface and they are responsible for attachment to host receptors. 50 , 51 The M protein has three transmembrane domains and it shapes the virions, promotes membrane curvature, and binds to the nucleocapsid. 52 , 53 The E protein plays a role in virus assembly and release, and it involved in viral pathogenesis. 54 , 55 The N protein contains two domains, both of which can bind virus RNA genome via different mechanisms. It is reported that N protein can bind to nsp3 protein to help tether the genome to RTC, and package the encapsidated genome into virions. 56 , 57 , 58 N is also an antagonist of interferon (IFN) and viral encoded repressor of RNA interference, which appears to be beneficial for the viral replication. 59

3.1. Diversity of CoV pathogenesis

Different CoVs display diverse host range and tissue tropism. Usually, alphacoronaviruses and betacoronaviruses infect mammals. In contrast, gammacoronaviruses and deltacoronaviruses infect birds and fish, but some of them can also infect mammals. 4 , 60 Before 2019, there were only six CoVs that were known to infect human and cause respiratory diseases. HCoV‐229E, HCoV‐OC43, HCoV‐NL63, and HKU1 cause only mild upper respiratory disease, and in rare cases some of them can cause severe infection in infants, young children and elders. SARS‐CoV and MERS‐CoV can infect lower respiratory tract and cause severe respiratory syndrome in human. 56 , 61 Some CoVs can infect livestock, birds, bats, mice, whales, and many other wild animals, and they can cause great economic loss. For example, in 2016, an HKU2‐related bat CoV, swine acute diarrhea syndrome CoV, caused a large‐scale outbreak of fatal disease in pigs in Southern China, and more than 24 000 piglets were dead. 62 This is the first documented spillover of a bat CoV that caused severe disease in livestock. 4 , 63

The new CoV, 2019‐nCoV, which belongs to betacoronaviruses based on sequence analysis (Figure 1A), can also infect the lower respiratory tract and cause pneumonia in human, but it seems that the symptoms are milder than SARS and MERS. Up to 20 January 2020, 291 cases in total have been confirmed in China by sequence analysis, clinical diagnosis and epidemiological examination, including 270 cases in Wuhan and 21 cases in Beijing, Shanghai, and Guangdong (http://www.nhc.gov.cn/yjb/new_index.shtml). In addition, four cases were confirmed in three other countries, including two cases in Thailand, one case in Japan, and one case in South Korea; all these patients had stayed in or visited Wuhan 2 weeks before the onset of the symptoms. Six deaths and 63 patients with severe symptoms were reported in Wuhan (http://wjw.wuhan.gov.cn/). Among the six death cases, four patients with published information are elder people of over 60 years old and have other illnesses before the infection, such as abdominal tumor and chronic liver disease, myocarditis and renal dysfunction, and cardiovascular disease.

Many of the patients have direct or indirect contact with the Wuhan Huanan Seafood Wholesale Market that is believed to be the original place of the outbreak of the 2019‐nCoV. However, transmission of 2019‐nCoV from fish to human is unlikely. The 2019‐nCoV and fish CoVs such as Beluga Whale CoV/SW1 belong to different genera and apparently have different host ranges. As the Wuhan seafood market also sells other animals, the natural host of 2019‐nCoV awaits to be identified. Due to the possibility of transmission from animal to human, CoVs in livestock and other animals including bats and wild animals sold in the market should be constantly monitored. In addition, more and more evidence indicate the new virus 2019‐nCoV is spread via the route of human‐to‐human transmission because there are infections of people who did not visit Wuhan but had close contact with family members who had visited Wuhan and got infected (http://www.cctv.com/).

The major pathogenic CoVs are listed in Table 2 for better understanding the pathogenesis of CoVs.

Table 2

List of important pathogenic coronaviruses

VirusGenusHostSymptoms
Human CoV‐229EAlphaHumanMild respiratory tract infections
Human CoV‐NL63AlphaHumanMild respiratory tract infections
PRCV/ISU‐1AlphaPigMild respiratory tract infections
TGEV/PUR46‐MADAlphaPigDiarrhea, with 100% mortality in piglets less than 2‐wk‐old
PEDV/ZJU‐G1‐2013AlphaPigSevere watery diarrhea
SeACoV‐CH/GD‐01AlphaPigSevere and acute diarrhea and acute vomiting
Canine CoV/TU336/F/2008AlphaDogMild clinical signs, diarrhea
Camel alphacoronavirus isolate camel/RiyadhAlphaCamelAsymptomatic
Feline infectious peritonitis virusAlphaCatFever, vasculitis, and serositis, with or without effusions
Human CoV‐HKU1BetaHumanPneumonia
Human CoV‐OC43BetaHumanMild respiratory tract infections
SARS‐CoVBetaHumanSevere acute respiratory syndrome, 10% mortality rate
MERS‐CoVBetaHumanSevere acute respiratory syndrome, 37% mortality rate
Bovine CoV/ENTBetaCowDiarrhea
Equine CoV/Obihiro12‐1BetaHorseFever, anorexia, leucopenia
MHV‐A59BetaMouseAcute pneumonia and severe lung injuries
Beluga Whale CoV/SW1GammaWhalePulmonary disease, terminal acute liver failure
IBVGammaChickenSevere respiratory disease
Bulbul coronavirus HKU11DeltaBulbulRespiratory disease (collected from respiratory tract of dead wild birds)
Sparrow coronavirus HKU17DeltaSparrowRespiratory disease (collected from respiratory tract of dead wild birds)
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

4. TREATMENT AND PREVENTION

At present, there is no single specific antiviral therapy for CoV and the main treatments are supportive. Recombinant IFN with ribavirin only has limited effects against CoVs infection. 64 After SARS and MERS epidemics, great efforts have been devoted to development of new antivirals targeting CoVs proteases, polymerases, MTases, and entry proteins, however, none of them has been shown to be efficacious in clinical trials. 65 , 66 , 67 Plasma and antibodies obtained from the convalescent patients have been proposed for use in treatment. 68

In addition, various vaccine strategies, such as using inactivated viruses, live‐attenuated viruses, viral vector‐based vaccines, subunit vaccines, recombinant proteins, and DNA vaccines, have been developed but have only been evaluated in animals so far. 69 , 70

Since there is no effective therapy or vaccine, the best measures now are to control the source of infection, early diagnosis, reporting, isolation, supportive treatments, and timely publishing epidemic information to avoid unnecessary panic. For individuals, good personal hygiene, fitted mask, ventilation, and avoiding crowded places will help to prevent CoVs infection.

ACKNOWLEDGMENTS

This study was supported by the Natural Science Foundation of China (Grant No.: #81620108020 and #81672008), National Science and Technology Major Project (#2018ZX10733403), Shenzhen Science and Technology Program (Grant No.: KQTD20180411143323605) and Guangdong Provincial “Zhujiang Talents Program” (2017).

Notes

Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–423. 10.1002/jmv.25681 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Contributor Information

Yu Chen, nc.ude.uhw@uynehc.

Deyin Guo, nc.ude.usys.liam@niyedoug.

REFERENCES

1. Wang LF, Shi Z, Zhang S, Field H, Daszak P, Eaton B. Review of bats and SARS. Emerg Infect Dis. 2006;12(12):1834‐1840. [PMC free article] [PubMed] [Google Scholar]
2. Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS‐like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535‐538. [PMC free article] [PubMed] [Google Scholar]
3. Chen Y, Guo D. Molecular mechanisms of coronavirus RNA capping and methylation. Virol Sin. 2016;31(1):3‐11. [PMC free article] [PubMed] [Google Scholar]
4. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181‐192. [PMC free article] [PubMed] [Google Scholar]
5. Cauchemez S, Van Kerkhove MD, Riley S, Donnelly CA, Fraser C, Ferguson NM. Transmission scenarios for Middle East respiratory syndrome coronavirus (MERS‐CoV) and how to tell them apart. Euro Surveill. 2013;18(24):pii: 20503. [PMC free article] [PubMed] [Google Scholar]
6. Snijder EJ, van der Meer Y, Zevenhoven‐Dobbe J, et al. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J Virol. 2006;80(12):5927‐5940. [PMC free article] [PubMed] [Google Scholar]
7. Hussain S, Pan J, Chen Y, et al. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J Virol. 2005;79(9):5288‐5295. [PMC free article] [PubMed] [Google Scholar]
8. Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. J Virol. 2007;81(1):20‐29. [PMC free article] [PubMed] [Google Scholar]
9. Perlman S, Netland J. Coronaviruses post‐SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7(6):439‐450. [PMC free article] [PubMed] [Google Scholar]
10. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193‐292. [PMC free article] [PubMed] [Google Scholar]
11. Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus‐encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol. 2000;81(Pt 4):853‐879. [PubMed] [Google Scholar]
12. Eckerle LD, Becker MM, Halpin RA, et al. Infidelity of SARS‐CoV Nsp14‐exonuclease mutant virus replication is revealed by complete genome sequencing. PLOS Pathog. 2010;6(5):e1000896. [PMC free article] [PubMed] [Google Scholar]
13. Ogando NS, Ferron F, Decroly E, Canard B, Posthuma CC, Snijder EJ. The curious case of the nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity. Front Microbiol. 2019;10:1813. [PMC free article] [PubMed] [Google Scholar]
14. Smith EC, Blanc H, Vignuzzi M, Denison MR. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLOS Pathog. 2013;9(8):e1003565. [PMC free article] [PubMed] [Google Scholar]
15. Huang C, Lokugamage KG, Rozovics JM, Narayanan K, Semler BL, Makino S. SARS coronavirus nsp1 protein induces template‐dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1‐induced RNA cleavage. PLOS Pathog. 2011;7(12):e1002433. [PMC free article] [PubMed] [Google Scholar]
16. Tanaka T, Kamitani W, DeDiego ML, Enjuanes L, Matsuura Y. Severe acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specific translational shutoff of host mRNA. J Virol. 2012;86(20):11128‐11137. [PMC free article] [PubMed] [Google Scholar]
17. Graham RL, Sims AC, Brockway SM, Baric RS, Denison MR. The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication. J Virol. 2005;79(21):13399‐13411. [PMC free article] [PubMed] [Google Scholar]
18. Gadlage MJ, Graham RL, Denison MR. Murine coronaviruses encoding nsp2 at different genomic loci have altered replication, protein expression, and localization. J Virol. 2008;82(23):11964‐11969. [PMC free article] [PubMed] [Google Scholar]
19. Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: structures and functions of a large multi‐domain protein. Antiviral Res. 2018;149:58‐74. [PMC free article] [PubMed] [Google Scholar]
20. Serrano P, Johnson MA, Chatterjee A, et al. Nuclear magnetic resonance structure of the nucleic acid‐binding domain of severe acute respiratory syndrome coronavirus nonstructural protein 3. J Virol. 2009;83(24):12998‐13008. [PMC free article] [PubMed] [Google Scholar]
21. Beachboard DC, Anderson‐Daniels JM, Denison MR. Mutations across murine hepatitis virus nsp4 alter virus fitness and membrane modifications. J Virol. 2015;89(4):2080‐2089. [PMC free article] [PubMed] [Google Scholar]
22. Gadlage MJ, Sparks JS, Beachboard DC, et al. Murine hepatitis virus nonstructural protein 4 regulates virus‐induced membrane modifications and replication complex function. J Virol. 2010;84(1):280‐290. [PMC free article] [PubMed] [Google Scholar]
23. Stobart CC, Sexton NR, Munjal H, et al. Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity. J Virol. 2013;87(23):12611‐12618. [PMC free article] [PubMed] [Google Scholar]
24. Zhu X, Fang L, Wang D, et al. Porcine deltacoronavirus nsp5 inhibits interferon‐beta production through the cleavage of NEMO. Virology. 2017;502:33‐38. [PMC free article] [PubMed] [Google Scholar]
25. Zhu X, Wang D, Zhou J, et al. Porcine deltacoronavirus nsp5 antagonizes type I interferon signaling by cleaving STAT2. J Virol. 2017;91(10):pii: e00003‐17. [PMC free article] [PubMed] [Google Scholar]
26. Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double‐membrane vesicles. mBio. 2013;4(4):pii: e00524‐13. [PMC free article] [PubMed] [Google Scholar]
27. Cottam EM, Whelband MC, Wileman T. Coronavirus NSP6 restricts autophagosome expansion. Autophagy. 2014;10(8):1426‐1441. [PMC free article] [PubMed] [Google Scholar]
28. Kirchdoerfer RN, Ward AB. Structure of the SARS‐CoV nsp12 polymerase bound to nsp7 and nsp8 co‐factors. Nat Commun. 2019;10(1):2342. [PMC free article] [PubMed] [Google Scholar]
29. Zhai Y, Sun F, Li X, et al. Insights into SARS‐CoV transcription and replication from the structure of the nsp7‐nsp8 hexadecamer. Nat Struct Mol Biol. 2005;12(11):980‐986. [PMC free article] [PubMed] [Google Scholar]
30. te Velthuis AJ, van den Worm SH, Snijder EJ. The SARS‐coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. Nucleic Acids Res. 2012;40(4):1737‐1747. [PMC free article] [PubMed] [Google Scholar]
31. Egloff MP, Ferron F, Campanacci V, et al. The severe acute respiratory syndrome‐coronavirus replicative protein nsp9 is a single‐stranded RNA‐binding subunit unique in the RNA virus world. Proc Natl Acad Sci USA. 2004;101(11):3792‐3796. [PMC free article] [PubMed] [Google Scholar]
32. Zeng Z, Deng F, Shi K, et al. Dimerization of coronavirus nsp9 with diverse modes enhances its nucleic acid binding affinity. J Virol. 2018;92(17):e00692‐18. [PMC free article] [PubMed] [Google Scholar]
33. Bouvet M, Lugari A, Posthuma CC, et al. Coronavirus Nsp10, a critical co‐factor for activation of multiple replicative enzymes. J Biol Chem. 2014;289(37):25783‐25796. [PMC free article] [PubMed] [Google Scholar]
34. Chen Y, Su C, Ke M, et al. Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2′‐O‐methylation by nsp16/nsp10 protein complex. PLOS Pathog. 2011;7(10):e1002294. [PMC free article] [PubMed] [Google Scholar]
35. Decroly E, Debarnot C, Ferron F, et al. Crystal structure and functional analysis of the SARS‐coronavirus RNA cap 2′‐O‐methyltransferase nsp10/nsp16 complex. PLOS Pathog. 2011;7(5):e1002059. [PMC free article] [PubMed] [Google Scholar]
36. Ma Y, Wu L, Shaw N, et al. Structural basis and functional analysis of the SARS coronavirus nsp14‐nsp10 complex. Proc Natl Acad Sci USA. 2015;112(30):9436‐9441. [PMC free article] [PubMed] [Google Scholar]
37. Fang SG, Shen H, Wang J, Tay FPL, Liu DX. Proteolytic processing of polyproteins 1a and 1ab between non‐structural proteins 10 and 11/12 of coronavirus infectious bronchitis virus is dispensable for viral replication in cultured cells. Virology. 2008;379(2):175‐180. [PMC free article] [PubMed] [Google Scholar]
38. Ahn DG, Choi JK, Taylor DR, Oh JW. Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA‐dependent RNA polymerase capable of copying viral RNA templates. Arch Virol. 2012;157(11):2095‐2104. [PMC free article] [PubMed] [Google Scholar]
39. te Velthuis AJW, Arnold JJ, Cameron CE, van den Worm SHE, Snijder EJ. The RNA polymerase activity of SARS‐coronavirus nsp12 is primer dependent. Nucleic Acids Res. 2010;38(1):203‐214. [PMC free article] [PubMed] [Google Scholar]
40. Adedeji AO, Lazarus H. Biochemical characterization of Middle East respiratory syndrome coronavirus helicase. mSphere. 2016;1:5. [PMC free article] [PubMed] [Google Scholar]
41. Hao W, Wojdyla JA, Zhao R, et al. Crystal structure of Middle East respiratory syndrome coronavirus helicase. PLOS Pathog. 2017;13(6):e1006474. [PMC free article] [PubMed] [Google Scholar]
42. Jia Z, Yan L, Ren Z, et al. Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis. Nucleic Acids Res. 2019;47(12):6538‐6550. [PMC free article] [PubMed] [Google Scholar]
43. Bouvet M, Imbert I, Subissi L, Gluais L, Canard B, Decroly E. RNA 3′‐end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. Proc Natl Acad Sci USA. 2012;109(24):9372‐9377. [PMC free article] [PubMed] [Google Scholar]
44. Chen Y, Cai H, Pan J, et al. Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase. Proc Natl Acad Sci USA. 2009;106(9):3484‐3489. [PMC free article] [PubMed] [Google Scholar]
45. Minskaia E, Hertzig T, Gorbalenya AE, et al. Discovery of an RNA virus 3′→5′ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci USA. 2006;103(13):5108‐5113. [PMC free article] [PubMed] [Google Scholar]
46. Bhardwaj K, Sun J, Holzenburg A, Guarino LA, Kao CC. RNA recognition and cleavage by the SARS coronavirus endoribonuclease. J Mol Biol. 2006;361(2):243‐256. [PMC free article] [PubMed] [Google Scholar]
47. Deng X, Hackbart M, Mettelman RC, et al. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proc Natl Acad Sci USA. 2017;114(21):E4251‐E4260. [PMC free article] [PubMed] [Google Scholar]
48. Zhang L, Li L, Yan L, et al. Structural and biochemical characterization of endoribonuclease Nsp15 encoded by middle east respiratory syndrome coronavirus. J Virol. 2018;92(22):pii: e00893‐18. [PMC free article] [PubMed] [Google Scholar]
49. Shi P, Su Y, Li R, Liang Z, Dong S, Huang J. PEDV nsp16 negatively regulates innate immunity to promote viral proliferation. Virus Res. 2019;265:57‐66. [PMC free article] [PubMed] [Google Scholar]
50. Beniac DR, Andonov A, Grudeski E, Booth TF. Architecture of the SARS coronavirus prefusion spike. Nat Struct Mol Biol. 2006;13(8):751‐752. [PMC free article] [PubMed] [Google Scholar]
51. Delmas B, Laude H. Assembly of coronavirus spike protein into trimers and its role in epitope expression. J Virol. 1990;64(11):5367‐5375. [PMC free article] [PubMed] [Google Scholar]
52. Nal B. Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. J Gen Virol. 2005;86(Pt 5):1423‐1434. [PubMed] [Google Scholar]
53. Neuman BW, Kiss G, Kunding AH, et al. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol. 2011;174(1):11‐22. [PMC free article] [PubMed] [Google Scholar]
54. DeDiego ML, Alvarez E, Almazan F, et al. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol. 2007;81(4):1701‐1713. [PMC free article] [PubMed] [Google Scholar]
55. Nieto‐Torres JL, DeDiego ML, Verdiá‐Báguena C, et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLOS Pathog. 2014;10(5):e1004077. [PMC free article] [PubMed] [Google Scholar]
56. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1‐23. [PMC free article] [PubMed] [Google Scholar]
57. Chang C, Sue SC, Yu T, et al. Modular organization of SARS coronavirus nucleocapsid protein. J Biomed Sci. 2006;13(1):59‐72. [PMC free article] [PubMed] [Google Scholar]
58. Hurst KR, Koetzner CA, Masters PS. Identification of in vivo‐interacting domains of the murine coronavirus nucleocapsid protein. J Virol. 2009;83(14):7221‐7234. [PMC free article] [PubMed] [Google Scholar]
59. Cui L, Wang H, Ji Y, et al. The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mammalian cells. J Virol. 2015;89(17):9029‐9043. [PMC free article] [PubMed] [Google Scholar]
60. Woo PCY, Lau SKP, Lam CSF, et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012;86(7):3995‐4008. [PMC free article] [PubMed] [Google Scholar]
61. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490‐502. [PMC free article] [PubMed] [Google Scholar]
62. Zhou P, Fan H, Lan T, et al. Fatal swine acute diarrhoea syndrome caused by an HKU2‐related coronavirus of bat origin. Nature. 2018;556(7700):255‐258. [PMC free article] [PubMed] [Google Scholar]
63. Simas PVM, Barnabé ACS, Durães‐Carvalho R, et al. Bat coronavirus in Brazil related to appalachian ridge and porcine epidemic diarrhea viruses. Emerg Infect Dis. 2015;21(4):729‐731. [PMC free article] [PubMed] [Google Scholar]
64. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293‐294. [PMC free article] [PubMed] [Google Scholar]
65. Chan JFW, Chan KH, Kao RYT, et al. Broad‐spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67(6):606‐616. [PMC free article] [PubMed] [Google Scholar]
66. Cheng KW, Cheng SC, Chen WY, et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain‐like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015;115:9‐16. [PMC free article] [PubMed] [Google Scholar]
67. Wang Y, Sun Y, Wu A, et al. Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10‐derived peptide in vitro and in vivo to reduce replication and pathogenesis. J Virol. 2015;89(16):8416‐8427. [PMC free article] [PubMed] [Google Scholar]
68. Mair‐Jenkins J, Saavedra‐Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta‐analysis. J Infect Dis. 2015;211(1):80‐90. [PMC free article] [PubMed] [Google Scholar]
69. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013;11(12):836‐848. [PMC free article] [PubMed] [Google Scholar]
70. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523‐534. [PMC free article] [PubMed] [Google Scholar]
Articles from Journal of Medical Virology are provided here courtesy of Wiley
-